Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Prostatic Neoplasms 11Neoplasm Metastasis 7Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Histiocytoma, Malignant Fibrous 3Head and Neck Neoplasms 3Dermatofibrosarcoma 3Bone Neoplasms 3Urinary Bladder Neoplasms 2Solid Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Recurrent Squamous Cell Lung Carcinoma 1Pathologic Complete Response 1Ovarian Neoplasms 1

Interventions

Gemcitabine 2Taxes 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Gene Expression Profiling 1Docetaxel 1Cisplatin 1Capecitabine 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Unknown Primary × Docetaxel × Clear all
NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡